Fabry-betegség: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• SGLT2 0
• GIP 0
• VEGF 0

190 intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NINDS · U01

  Advancing Ex Vivo Gene Therapy: IND-Enabling Studies for ASAH1-related SMA-PME

  Cedars-Sinai Medical Center· Los Angeles, Egyesült Államok· 825 159 USD awarded in fiscal year 2026· until 2028. aug.

• NIH NIAID · R01

  Risk factors of alpha-gal syndrome: investigating the human genetic risk factors and the tick salivary sensitizer

  Kansas State University· Manhattan, Egyesült Államok· 662 390 USD awarded in fiscal year 2026· until 2031. júl.

• NIH NINDS · F32

  Mechanisms of Neuronal Excitability and Pain in Fabry Disease

  Medical College of Wisconsin· Milwaukee, Egyesült Államok· 79 348 USD awarded in fiscal year 2026· until 2027. júl.

• European Commission (Horizon Europe) · HORIZON-ERC

  Coherent Control of a Nuclear Transition (COCONUT)

  Technische Universitaet Wien· Wien, Ausztria· EU contribution 3 479 505 EUR· until 2031. okt.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Refractive Index Observer (RIO)

  Eidgenoessische Technische Hochschule Zuerich· Zuerich, Svájc· EU contribution 150 000 EUR· until 2027. jún.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Casimir Self-Assembly out of Equilibrium (CASAlibra)

  Chalmers Tekniska Hogskola Aktiebolag· Goteborg, Svédország· EU contribution 2 469 830 EUR· until 2030. dec.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Electrically tunable cavity-coupled conducting polymer plasmonic antenna arrays for adaptive radiative cooling (ET-CPAARC)

  Linkopings Universitet· Linkoping, Svédország· EU contribution 236 340 EUR· until 2027. okt.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Novel ultrafast fiber microlaser for applications in Microwave Photonics and Communication Networks (MicroLight)

  Centre National de la Recherche Scientifique Cnrs· Paris, Franciaország· EU contribution 226 421 EUR· until 2027. szept.

  The disease is named only in the funder's project summary, not in the title.

8 of 10 running projects, newest first. Listed amounts together: 1,6 M USD + 8,6 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  A Study of Home vs Hospital Treatment in People With Fabry, Gaucher or Hunter Conditions in Mexico

  NCT07494058· Takeda· Frissítve: 2026. szept. 11.

  “Study was terminated early due to structural and methodological limitations identified in the primary data sources impacting validity, completeness, and clinical robustness of the expected results”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Cardiovasculorenal Phenotyping in Fabry Disease Through Noninvasive Testing

  NCT05699265· Children's Hospital Medical Center, Cincinnati· Frissítve: 2025. jún. 19.

  “The sponsor withdrew funding since there was no progress with this study for a significant amount of time.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Screening for Fabry Disease in Renal Transplantation

  NCT03886714· University Hospital, Montpellier· Frissítve: 2025. máj. 16.

  “Low recreuitement numbers and end of grant.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Study of the Effects of Fabrazyme Treatment on Lactation and Infants

  NCT00230607· Genzyme, a Sanofi Company· Frissítve: 2024. ápr. 10.

  “Per FDA decision, the 2003 Post Marketing commitment has been fulfilled.”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Evaluation of Phenotypic Variability in Fabry Disease

  NCT03145779· Boston Children's Hospital· Frissítve: 2020. dec. 3.

  “Funding”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Agalsidase Beta Long-Term Treatment Outcome for Fabry Disease Patients With IVS4 Mutation in Taiwan

  NCT06052800· Sanofi· Forrás

• A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease

  NCT05206773· Sanofi· Forrás

• A Study of Home vs Hospital Treatment in People With Fabry, Gaucher or Hunter Conditions in Mexico

  NCT07494058· Takeda· Forrás

• A Study of Replagal in Children and Adults With Fabry Disease in India

  NCT05067868· Shire· Forrás

• A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease

  NCT05280548· Sanofi· Forrás

• Early Detection of Fabry Disease

  NCT05106764· Takeda· Forrás

• A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease

  NCT07187440· Takeda· Forrás

• A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme

  NCT06019728· Sanofi· Forrás

• A Study of REPLAGAL® in Treatment-naive Chinese Participants With Fabry Disease

  NCT04974749· Takeda· Forrás

• Study of the Effects of Fabrazyme Treatment on Lactation and Infants

  NCT00230607· Genzyme, a Sanofi Company· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Organoids 1
• Exome Sequencing 1
• Proteomics 3
• Flow Cytometry 1
• Magnetic Resonance Imaging 5
• Deep Learning 1
• Cohort Studies 7
• Genome-Wide Association Study 2

• Prevalence of Fabry disease GLA variants among patients with parapelvic cysts: a Multicenter Italian Cohort Study.

  J Nephrol, 2026. okt.

• Prevalence and determinants of asymmetric septal hypertrophy (ASH) in diseases of left ventricular hypertrophy (LVH).

  Eur Heart J Cardiovasc Imaging, 2026. szept.

• Phenotype, genotype and prognosis of apical hypertrophic cardiomyopathies: a French multicentric cohort.

  Eur Heart J Cardiovasc Imaging, 2026. júl.

• Increased Risk of Injury in Patients with Fabry Disease: A Nationwide Population-Based Cohort Study in Taiwan.

  Int J Med Sci, 2026. máj.

• Unexpected genotypes associated with severe paediatric conditions identified in a healthy population cohort.

  Eur J Hum Genet, 2026. jan.

• Risk factors, stroke rates and aspirin prescribing trends in the Canadian Fabry disease initiative cohort.

  Orphanet J Rare Dis, 2025. nov.

• Stroke in Fabry Disease: Identification of Risk Factors for Stroke in a Large Single-Centre Cohort.

  Eur J Neurol, 2025. nov.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.